Keros Therapeutics, Inc. cash flow to debt ratio of 636.76% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Keros Therapeutics, Inc.'s free cash flow has increased -165.08% from $-162.80M last year to $105.95M, signaling increasing performance

Keros Therapeutics, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Keros Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.03 last year to 0.06 today, signaling weakened financials

Keros Therapeutics, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Keros Therapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Keros Therapeutics, Inc.'s profit margin has increased (-89.51%) in the last year from -5.28K% to -553.88%, signaling increasing performance

Keros Therapeutics, Inc.'s short-term assets of $315.43M exceed its short-term liabilities of $20.41M

Keros Therapeutics, Inc.'s return on assets of -28.91% is lower than the 5.00% threshold, indicating inefficient asset utilization

Keros Therapeutics, Inc.'s return on equity of -21.40%, is lower than 15.00%, indicating bad performance

Keros Therapeutics, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Keros Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Keros Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Keros Therapeutics, Inc. has a free cash flow yield of 30.98%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Keros Therapeutics, Inc.'s yearly earnings has increased -146.44% since last year from $-187.35M to $87.01M, signaling increasing performance

Keros Therapeutics, Inc.'s yearly revenue has increased 6.77K% since last year from $3.55M to $244.06M, signaling increasing performance

ROIC -35.25% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Keros Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Keros Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Keros Therapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Keros Therapeutics, Inc. has insufficient data to evaluate this check.

Keros Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Keros Therapeutics, Inc. is undervalued relative to its fair value price of 20.84 based on EBITDA multiple model

Keros Therapeutics, Inc. has an EV/EBITDA ratio of 0.77x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Keros Therapeutics, Inc. has insufficient data to evaluate this check.

Keros Therapeutics, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Keros Therapeutics, Inc. has a price-to-book ratio of 0.81x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Keros Therapeutics, Inc. has a price-to-sales ratio of 14.10x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue